Examples of the present disclosure relate generally to medical devices, and methods for manufacturing and using these medical devices. In particular, examples of the present disclosure relate to catheters and methods for manufacturing and using catheters for applying energy to tissue (e.g., airway passageways in a lung) in a minimally invasive procedure.
Chronic obstructive pulmonary disease (COPD) includes conditions such as, e.g., chronic bronchitis and emphysema. COPD currently affects over 15 million people in the United States alone and is currently the third leading cause of death in the country. The primary cause of COPD is the inhalation of cigarette smoke, responsible for over 90% of COPD cases. The economic and social burden of the disease is substantial and is increasing.
Chronic bronchitis is characterized by chronic cough with sputum production. Due to airway inflammation, mucus hypersecretion, airway hyper-responsiveness, and eventual fibrosis of the airway walls, significant airflow and gas exchange limitations result.
Emphysema is characterized by the destruction or damage of the lung parenchyma. This destruction of the lung parenchyma leads to a loss of elastic recoil and tethering which maintains airway patency. Because bronchioles are not supported by cartilage like the larger airways, they have little intrinsic support and therefore are susceptible to collapse when destruction of tethering occurs, particularly during exhalation.
Acute exacerbations of COPD (AECOPD) often require emergency care and inpatient hospital care. An AECOPD is defined by a sudden worsening of symptoms (e.g., increase in or onset of cough, wheeze, and sputum changes) that typically last for several days, but can persist for weeks. An AECOPD is typically triggered by a bacterial infection, viral infection, or pollutants, which manifest quickly into airway inflammation, mucus hypersecretion, and bronchoconstriction, causing significant airway restriction.
Despite relatively efficacious drugs (e.g., long-acting muscarinic antagonists, long-acting beta agonists, corticosteroids, and antibiotics) that treat COPD symptoms, a particular segment of patients known as “frequent exacerbators” often visit the emergency room and hospital with exacerbations. These patients also have a more rapid decline in lung function, poorer quality of life, and a greater mortality risk.
Reversible obstructive pulmonary disease includes asthma and reversible aspects of COPD. Asthma is a disease in which bronchoconstriction, excessive mucus production, and inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma is further characterized by acute episodes of airway narrowing via contraction of hyper-responsive airway smooth muscle.
The reversible aspects of COPD include excessive mucus production and partial airway occlusion, airway narrowing secondary to smooth muscle contraction, and bronchial wall edema and inflation of the airways. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways, and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes.
In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process including, but not limited to, mast cells, eosinophils, T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in sensitivity and hyperresponsiveness of the airway smooth muscle cells lining the airways to particular stimuli.
The chronic nature of asthma can also lead to remodeling of the airway wall (e.g., structural changes such as airway wall thickening or chronic edema) that can further affect the function of the airway wall and influence airway hyper-responsiveness. Epithelial denudation exposes the underlying tissue to substances that would not normally otherwise contact the underlying tissue, further reinforcing the cycle of cellular damage and inflammatory response.
In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.
Bronchiectasis is a condition where lung airways become enlarged, flabby, and/or scarred. In the injured areas, mucus often builds up, causing obstruction and/or infections. A cycle of repeated infections may continue to damage the airways and cause greater mucus build-up. Bronchiectasis can lead to health problems such as respiratory failure, atelectasis, and heart failure.
Strategies for managing COPD and other conditions of the lung include smoking cessation, vaccination, rehabilitation, and drug treatments (e.g., inhalers or oral medication). Drug treatments of COPD conditions, such as, e.g., mucus production, inflammation, and bronchoconstriction often suffer from poor patient compliance. That is, certain patients may not accurately administer prescribed doses, reducing the efficacy of treatment. For drug treatments utilizing inhalation, there is also an accompanying drug loss due to upper airway entrapment, which may lead to an over-prescription of active drugs. Also, inhalation treatments can be ineffective at treating smaller airways of the lung (e.g., airways that are smaller than 2 mm). For drug treatments utilizing oral administration, there is an accompanying systemic loss which also leads to an over-prescription of active drugs. The over-prescription of drugs may result in suboptimal treatment and/or a build-up of toxins within the lungs and/or other organ systems. In other situations, drugs may not be deposited evenly to areas of the lungs because of particle size and/or blockage of airways preventing the drugs from reaching distal regions of the lungs (e.g., a heterogeneous delivery of drugs). Blockages may be caused by mucus and narrowing of the airway due to inflammation and remodelling.
The use of radiofrequency (RF) energy in medical applications is rapidly increasing. RF energy can be used to treat a variety of conditions affecting numerous body systems, such as, e.g., the respiratory system, the circulatory system, the digestive system, the immune system, the muscular system, among others. Various non-drug energy delivery procedures for, among other things, treatment of COPD, such as, e.g., severe persistent asthma, for which inhaled corticosteroids and long-acting beta-agonists are an insufficient treatment. In order to apply the energy delivery procedures, a catheter may be positioned to deliver thermal energy to a body lumen, such as a lung airway wall, for reducing excessive airway smooth muscle (ASM), and clear the air pathway within the trachea or lungs of a patient. The catheter may include an electrode array at a distal portion, which may be manually expanded to position the electrode array in communication with the airway wall. The electrode array may be coupled to one or more thermocouple wires for determining temperature of the electrode array to control the thermal energy delivered to the airway wall.
Conventionally, the electrode array can include elongated electrodes, which are welded together and coupled to hypotubes at their distal and proximal ends. Since the electrode array and the hypotubes are conductive to each other, welding of the electrode array only allows for monopolar design of delivering electrical energy to the electrode array. Moreover, in conventional arrangements, less space is available for the thermocouple wire to extend proximally through a proximal hypotube attached to the electrode array due to welding of the electrode array.
Therefore, there exists a need for an improved catheter design that permits different configurations (including, e.g., monopolar or bipolar configurations) for the delivery of electrical energy to body lumens, and increases effective space available for, among other things, thermocouple wire attachment. The improved catheter designs would also reduce the number of steps needed to assemble and/or manufacture the electrode array by, e.g., eliminating the need for welding together multiple electrodes of the electrode array. In other examples, there exists a need for other improvements. For example, certain electrode arrays, e.g., monopolar electrode arrays, may create uneven heating distribution, and may concentrate heating in the regions surrounding the electrodes to undesirable levels.
In one example, a medical device may include an expandable electrode assembly reciprocally movable between a first configuration and a second configuration. The expandable electrode assembly may include a first plurality of longitudinally extending legs formed in a first partially tubular member, a second plurality of longitudinally extending legs formed in a second partially tubular member, a first end piece formed by first ends of the first and second partially tubular members, and a second end piece formed by second ends of the first and second partially tubular members, wherein a portion of the second partially tubular member is configured to be received in a portion of the first partially tubular member.
Various examples of the medical device may include one or more of the following features: legs of first partially tubular member circumferentially alternate with legs of the second partially tubular member; the first ends of the first and second partially tubular members are substantially C-shaped or other shapes that are capable of being coupled, and the first end piece is formed by inserting the first end of the second partially tubular member into a volume partially defined by the first end of the first partially tubular member; when a portion of the second partially tubular member is received in a portion of the first partially tubular member, the first and second plurality of longitudinally extending legs define an expandable electrode array, such as a basket; the second end piece further includes an offset that extends longitudinally beyond the first end piece; an activation element disposed through first and second end pieces, the activation element configured to move the plurality of legs radially outward from the first configuration to the second configuration, and reciprocally back to the first configuration or the legs can have a shape memory effect that restores the legs to the first configuration; the activation element is electrically conductive and configured to deliver electrical energy to at least one of the first and second plurality of longitudinally extending legs; each of the first and second plurality of longitudinally extending legs includes: a first insulated section; a second insulated section, and an exposed electrically conductive section between the first and second insulated sections; the first and second end pieces are insulated; the second end of the second partially tubular member includes a circumferentially extending gap between first and second C-shaped portions, at least one of the second plurality of longitudinally extending legs extends from the first C-shaped portion, and at least one of the second plurality of longitudinally extending legs extends from the second C-shaped portion; the first end of the first partially tubular member includes a circumferentially extending gap between first and second C-shaped portions; at least one of the first plurality of longitudinally extending legs extends from the first C-shaped portion of the first partially tubular member, and at least one of the first plurality of longitudinally extending legs extends from the second C-shaped portion of the first partially tubular member; the first end piece further includes a first longitudinally extending gap disposed between circumferential ends of the first end piece, and the second end piece further includes a second longitudinally extending gap disposed between circumferential ends of the second end piece; a tube disposed around at least one leg of the first or second plurality of legs; a third longitudinally extending gap disposed in either first or second end of the first partially tubular member, the tube extending through the third longitudinally extending gap when the basket is in an expanded configuration; an endcap disposed through the first or second longitudinally extending gap, the endcap configured to prevent rotation of the first partially tubular member relative to the second partially tubular member.
In another example, a medical device may include a first partially tubular member having a first end, a second end, a first plurality of legs extending between the first and second ends of the first partially tubular member. The medical device may include a second partially tubular member including a first end, a second end, and a second plurality of legs extending between the first and second ends of the second partially tubular member, wherein the first ends of the first and second partially tubular members are coupled together, the second ends of the first and second partially tubular members are coupled together, and the first and second plurality of legs are disposed about a longitudinal axis of the medical device.
Various examples of the medical device may include one or more of the following features: legs of first partially tubular member circumferentially alternate with legs of the second partially tubular member; and the first and second ends of the first and second partially tubular members are C-shaped.
In another example, a method of delivering energy to a body lumen using a medical device may include inserting the medical device into the body lumen. The medical device may include a basket reciprocally movable between a collapsed configuration and an expanded configuration. The basket may include a first plurality of longitudinally extending legs formed in a first partially tubular member, a second plurality of longitudinally extending legs formed in a second partially tubular member, a first end piece formed by first ends of the first and second partially tubular members, and a second end piece formed by second ends of the first and second partially tubular members. The method may also include delivering electrical energy to the body lumen via at least one of the first or second plurality of legs.
In a further example, the legs of first partially tubular member circumferentially may alternate with legs of the second partially tubular member.
In yet another aspect, the present disclosure may be directed to a medical device. The medical device may include an expandable energy delivery array reciprocally movable between a first configuration and a second configuration. The expandable energy delivery array may include a first assembly having a first proximal end piece, a first distal end piece, and one or more first energy transfer elements extending between the first proximal and first distal end pieces, and a second assembly having a second proximal end piece, a second distal end piece, and one or more second energy transfer elements extending between the second proximal and second distal end pieces. The second proximal end piece may be proximal to the first proximal end piece, and the second distal end piece may be distal to the first distal end piece.
Various examples of the present disclosure may include one or more of the following features: wherein the first and second assemblies may be electrically insulated from one another; wherein the first and second proximal end pieces may be separated by an insulating element; wherein the first and second proximal end pieces may be longitudinally separated by the insulating element; wherein the first and second distal end pieces may be longitudinally separated by an insulating element; wherein the first and second energy transfer elements may radially alternate with one another relative to a longitudinal axis of the medical device; wherein the second energy transfer elements may extend through a notch disposed in an outer radial surface of the second distal end piece; wherein the first energy transfer elements may be disposed further from a longitudinal axis of the energy delivery array than the second energy transfer elements; wherein the second assembly may be configured to deliver energy through a body tissue to the first assembly; further including an activation element that may extend from a proximal end of the medical device through the first and second assemblies, the activation element being coupled to the second distal end piece; wherein longitudinal movement of the activation element may be configured to reciprocally move the energy delivery array between the first and second configurations, wherein the first configuration is a collapsed configuration and the second configuration may be a radially expanded configuration; wherein the activation element may be configured to deliver RF energy to the second assembly; wherein each of the first and second transfer elements may include an active region defined at proximal and distal portions by insulating regions, wherein the active region may be configured to deliver RF energy to body tissues when in contact with the body tissues, and the insulating regions are not configured to deliver RF energy to body tissues at any time; wherein the active region of at least one first or second energy transfer element may include at least one temperature sensing element configured to sense a temperature of the active region or of body tissue; wherein the energy delivery array may be configured to deliver energy to body tissues in a bipolar configuration.
In yet another aspect the present disclosure may be directed to a medical device. The medical device may be an expandable energy delivery array reciprocally movable between a first configuration and a second configuration. The expandable energy delivery array may include one or more first energy transfer elements, and one or more second energy transfer elements. The one or more first energy transfer elements may alternate with the one or more second energy transfer elements radially about a longitudinal axis of the energy delivery array, and the one or more first energy transfer elements may be spaced further from the longitudinal axis of the energy delivery array than the one or more second energy transfer elements.
Various aspects of the present disclosure may also include the following feature: an activation element that may extend from a proximal end towards a distal end of the medical device, the activation element configured to deliver energy to the one or more second energy transfer elements.
In yet another aspect, the present disclosure may be directed to a method of delivering energy to a body. The method may include inserting an energy delivery array having one or more first energy transfer elements and one or more second energy transfer elements into a lumen of the body. The one or more first energy transfer elements may be disposed further from a longitudinal axis of the energy delivery array than the one or more second energy transfer elements. The method may also include radially expanding the one or more first and second transfer elements to contact tissues defining the lumen, and delivering energy from the one or more second energy transfer elements, through the tissues, to the one or more first energy transfer elements.
Various aspects of the present disclosure may include one or more of the following features: radially expanding the one or more first and second transfer elements by longitudinally moving an activation element extending through a space defined by the first and second energy transfer elements; and delivering energy to the one or more second energy transfer elements via the activation element.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate exemplary examples of the present disclosure and together with the description, serve to explain principles of the disclosure.
Reference will now be made in detail to exemplary examples of the present disclosure, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. The term “distal” may refer to the end farthest away from a user when introducing a device into a patient. By contrast, the term “proximal” may refer to the end closest to the user when placing the device into the patient.
Examples of the present disclosure relate to medical devices used for applying energy to tissue during minimally invasive procedures. For example, examples of a disclosed catheter and method of use are contemplated. In some examples, an expandable catheter, e.g., a radiofrequency (RF) catheter, including elongated electrodes (configured in an expandable electrode array) may be advanced into tissue of a patient's body. The catheter may be bipolar or monopolar, and may be configured to expand within a body lumen to deliver electrical energy to elongated electrodes located at a distal portion of the catheter. The catheters may be constructed without welding the electrodes together. In particular, the catheter can be used in a procedure, such as, e.g., an energy delivery procedure, where energy may be transferred to target tissue (e.g., lung tissue) by the RF catheter electrode. Energy delivery procedures may use the catheter to deliver thermal energy to an airway wall in a controlled manner to eliminate or otherwise reduce excessive ASM. To apply an energy during an energy delivery procedure, the catheter may be positioned at a desired location within the airway. An electrode cage or array may be disposed at a distal portion of the catheter, and may be selectively expanded to contact the airway wall. The RF electrodes may be expanded manually by squeezing a handle (or actuating another suitable actuator) of the catheter by applying an appropriate expansion force.
Initially, those of ordinary skill in the art will understand that any of the examples disclosed herein may include one or more of the features discussed in connection with another of the other examples disclosed herein.
The distal portion of catheter 100 may be used to ablate or otherwise deliver energy to tissue inside the body of a patient for treatment. As shown in
A length of activation element 104 extending through electrode cage 102 may also extend through expansion supporters 106, 107. Expansion supporters 106, 107, the longitudinal gaps between the electrodes 10, 11, and a hypotube 108 may facilitate buckling of electrodes 10, 11. The buckling of electrodes 10, 11 may allow electrode cage 102 to reciprocally move between the collapsed configuration and an expanded configuration, in which each electrode of the electrode cage bows radially outward. In some examples, electrodes 10, 11 may include a shape memory material that restores electrodes 10, 11 to the collapsed or expanded configuration. Hypotube or cap 108 may be located at a distal end of the electrode cage 102 to support and provide resilience to electrode cage 102.
In one example, each of electrode panels 202, 203 (referring to
Longitudinal sections may be removed from between distal portion 22 and proximal portion 24 of electrode panel 202 to form electrodes 10 and 11 separated by a longitudinal gap 18. Similarly, the electrode panel 203 may have electrode ribbons 12 and 13 separated by a longitudinal gap 20. Although each of the electrode panels 202, 203 have been shown to have two electrodes, a greater or lesser number of electrodes may be utilized in alternative examples. The removal of the longitudinal sections may cause the transverse lengths of distal portion 22 and proximal portion 24 of electrode panel 202 to become relatively longer than the combined width of electrodes 10, 11 and longitudinal gap 18. Similarly, the removal of the longitudinal sections may cause the transverse lengths of distal portion 23 and proximal portion 25 of electrode panel 203 to become relatively longer than the combined width of electrodes 12, 13 and longitudinal gap 20, The electrodes 10, 11, 12, and 13 may be longitudinally extending legs having substantially the same or a variable cross-section, each of which may be less than the width of inclusive longitudinal gaps 18, 20. As shown, electrodes 12, 13 may have a thicker cross-section at an interior portion (e.g., at a middle or central portion) for providing additional strength to electrodes 12, 13 and space for creating a channel. The sheets utilized to form electrode panels 202, 203 may have relatively different widths so that the electrode panels 202, 203 have different diameters when rolled.
Subsequently, electrode panels 202, 203 may be rolled to form a partially tubular member (
Further, the angular position of the electrodes 10, 11, 12, and 13 in electrode tubes 204, 205 can be controlled by the orientation of longitudinal gaps 18, 20 between them. That is, electrode tubes 204, 205 may be rotated relative to one another (as shown in
In electrode cage 102, inner electrode tube 205 may be detachably connected or permanently coupled to outer electrode tube 204 with either even spacing (
Electrode cage 102 may be monopolar or bipolar based on insulation arrangements between electrodes 202, 203. If electrodes 10, 11, 12, and 13 are not insulated from each other at one or both of distal portions 22, 23 and proximal portions 24, 25, electrode cage 102 may operate in monopolar fashion (
An offset X may be disposed between electrode tubes 204, 205 (
Referring to
Referring to
Further, once electrode tubes 204, 205 are interlocked to form electrode cage 102, an end cap 402 (referring to
Referring to
A system may include a controller (not shown) and a standard flexible bronchoscope including catheter 100. The controller may be configured to deliver RF electrical energy to electrodes 10, 11, 12, and 13 at the distal portion of catheter 100. During operation, catheter 100 may be, while in collapsed configuration, distally advanced into a body lumen, such as, e.g., a bronchial tree or airway of lungs through a natural opening of the body, such as, e.g., the nose or mouth. The bronchoscope may be then navigated to a target treatment site, for example, the most distal airway in a targeted bronchial lobe. Once a distal end portion of catheter 100 is positioned at the target treatment site, electrode cage 102 may be expanded to make electrodes 10, 11, 12, and 13 contact an inner wall of the airway. Expansion of electrodes 10-13 may be limited when contact is made with the inner airway wall. Subsequently, the controller, which may be connected to a hub assembly of catheter 100 at the proximal end, may be activated to deliver electrical energy via activation element 104 and electrodes 10, 11, 12, and 13 to the treatment site. The electrical energy may be delivered in monopolar or bipolar fashion by electrodes 10, 11, 12, and 13 to deliver energy (e.g., RF, ultrasonic, or thermal energy) to tissue, such as, e.g., lung tissue. Each of such activation of electrodes 10, 11, 12, and 13 may be controlled to deliver RF electrical energy at a certain power, temperature and/or period of time, in order to affect a certain treatment protocol, e.g., 10 seconds intervals, at a temperature of about 65 degrees Celsius, and up to about 15 Watts of power, in the case of a monopolar application. It should be noted that the activation period may be increased or decreased, if desired. However, the bipolar activation of electrodes 10, 11, 12, and 13 may reduce this activation period relative to the monopolar activation period. The delivered electrical energy may be controlled to create a precise delivery of thermal energy to the airway wall, e.g., to eliminate or otherwise reduce excessive ASM, and decrease the ability of the airways to constrict, thereby reducing the severity of COPD or other bronchial conditions. In some examples, this may reduce the frequency of asthma attacks. When the lung tissue or ASM is sufficiently reduced, or treatment is otherwise completed, e.g., the controller may be deactivated and activation element 104 may be relaxed to release the buckling of electrodes 10, 11, 12, and 13 to return electrode cage 102 to the collapsed configuration, so that catheter 100 may be removed from within the patient.
This energy delivery procedure may be minimally invasive and may be performed in one or more outpatient procedure visits, each treating a different area of the lungs and scheduled approximately one or more (e.g., three) weeks apart.
Although the examples described above are disclosed in the context of use with a bronchoscope, those skilled in the art will understand that the principles disclosed above can be applied to other types of devices and can be implemented in different ways without departing from the scope of the invention as defined by the claims. In particular, constructional details, including manufacturing techniques and materials, are well within the understanding of those of ordinary skill in the art and have not been disclosed in detail herein. These and other modifications and variations are well within the scope of the present disclosure and can be envisioned and implemented by those of ordinary skill in the art.
With reference now to
Energy delivery assembly 700 may include a plurality of electrode tubes 702, 704. Like electrode tubes 204, 205, electrode tubes 702, 704 may be fabricated from rolling flattened electrode panels (not shown). Electrode tube 704 may be substantially similar to one or both of electrode tubes 204, 205. For example, electrode tube 704 may include a plurality of electrodes 722, 724 separated by a longitudinal gap therebetween. Although only two electrodes 722, 724 are shown, a greater or lesser number of electrodes 722, 724 may be provided as desired. Electrodes 722, 724 may be coupled together by proximal and distal portions 730, 732, as described above in connection with the aforementioned examples. As a result of rolling, each of proximal and distal portion 730, 732 may include a C-shaped or substantially cylindrical configuration. Proximal and distal portions 730, 732 may each define a through passageway therein. One or both of electrodes 722, 724 may include insulation 726 (e.g., a suitable insulative covering) disposed on a portion of electrodes 722, 724. For example, as shown in
Electrode tube 702 may also include two electrodes 706, 708 separated by a longitudinal gap. However, any suitable number of electrodes may be provided. Electrodes 706, 708 may be substantially similar to electrodes 722, 724. For example, electrodes 706, 708 may be coupled to one another via a proximal portion 716 having a C-shaped or substantially cylindrical configuration. Further, electrodes 706, 708 may include proximal insulation 712 (which may or may not extend to proximal portion 716) and distal insulation 714. Unlike electrode tube 704, however, distal ends of electrodes 706, 708 may be left free or otherwise unconnected to one another. That is, electrode tube 702 may not include a distal portion to couple together the distal ends of electrodes 706, 708. Instead, the distal ends of electrodes 706, 708 may include geometric features configured to secure electrode tube 702 to electrode tube 704. For example, in one example, electrodes 706, 708 may include opposing bends 718, 720, respectively, for frictionally engaging distal portion 732 of electrode tube 704. Bends 718, 720 may be preformed, or may be formed during assembly of electrode tube 702 into electrode tube 704, as described below. In such examples, a distal endface of distal portion 732 may include corresponding notches for receiving and retaining bends 718, 720 therein, as shown in
As shown in
With reference now to
An energy delivery array 800 is shown in
First polar assembly 803 may include a proximal end piece 806 and a distal end piece 808. Proximal and distal end pieces 806 and 808 may be formed of any suitable electrically conductive material, such as, e.g., metals or alloys including one or more of copper, steel, platinum, plastic materials with a conductive metal insert or coating, or the like. End pieces 806 and 808 may be formed from substantially the same materials, or from different materials, if desired. End pieces 806 and/or 808 may be substantially elongate, hollow cylindrical members, or may be formed in another suitable configuration. Proximal end piece 806 may be coupled to distal end piece 808 by one or more energy transfer elements 810. In the example shown in
Energy transfer elements 810 may be coupled to proximal and distal end pieces 806 and 808 by any suitable mechanism including, but not limited to, welding, soldering, machining, adhesives, crimping, laser attachment, or the like. Energy transfer elements 810 may be coupled to any suitable surface of proximal and distal end pieces 806 and 808 such as, e.g., a longitudinal end surface, an inner radial surface, an outer radial surface, or any other suitable surface. Energy transfer elements 810 may be radially spaced from one another relative to a longitudinal axis 820 of energy delivery array 800. Energy transfer elements 810 may be formed from any suitable material, such as those used to form proximal and distal end pieces 806 and 808. In some examples, energy transfer elements also may be formed of a shape memory metal or alloy, such as, e.g., nitinol.
Second polar assembly 804 may include a proximal end piece 812 and a distal end piece 814. Proximal and distal end pieces 812 and 814 may be formed of substantially similar materials as proximal and distal end pieces 806 and 808 of first polar assembly 803, or from different materials, if desired. End pieces 812 and/or 814 may be substantially elongate, hollow cylindrical members, or may be formed in another suitable configuration. Proximal end piece 812 may be coupled to distal end piece 814 by one or more energy transfer elements 816. In the example shown in
Energy transfer elements 816 may be radially spaced from one another relative to longitudinal axis 820 of energy delivery array 800, and may be substantially similar to energy transfer elements 810 of first polar assembly 803, or may include a different configuration, if desired. Further, energy transfer elements 816 may be coupled to proximal and distal end pieces 812 and 814 in a substantially similar manner as energy transfer elements are coupled to proximal and distal end pieces 806 and 808 in first polar assembly 803.
In one example, however, energy transfer elements 816 may be received by recesses 818 formed in an outer radial surface of distal end piece 814. Similar to energy transfer elements 816, recesses 818 may be radially spaced from one another about longitudinal axis 820. In some examples, it is contemplated that proximal end piece 806, distal end piece 808, and proximal end piece 812 may alternatively or additionally include recesses formed in their respective outer radial surfaces for receiving an end of a given energy transfer element 810 or 816.
Energy transfer elements 810 may alternate with energy transfer elements 816 radially about longitudinal axis 820. Further, in some examples, energy transfer elements 810 may be disposed about a first circumference of energy delivery array 800, while energy transfer elements 816 may be disposed about a second circumference of energy delivery array 800. In one example, the first circumference may be spaced further from a central longitudinal axis (e.g., longitudinal axis 820) or radial center of electrode delivery array 800 than the second circumference. Thus, energy transfer elements 810 may be disposed further from a central longitudinal axis or radial center of energy delivery array 800 than energy transfer elements 816. However, it is contemplated that in some alternative examples, that energy transfer elements 816 may be disposed further from a central longitudinal axis (e.g., longitudinal axis 820) or radial center of energy delivery array 800 than energy transfer elements 810.
Each of energy transfer elements 810 and 816 may include an exposed active region 826 that is configured to deliver RF energy to body tissues. Active region 826 may be defined proximally and distally along energy transfer elements 810 and 816 by a proximal insulated region 828 and a distal insulated region 830. Along proximal insulated region 828 and distal insulated region 830, energy transfer elements 810 and 816 may be unable to deliver energy to bodily tissues. Proximal and distal insulated regions 828 and 830 may be formed from any suitable material, such as, e.g., a heat shrink sleeve, a dielectric polymeric coating, or other suitable material which may function as an insulator. Proximal and distal insulated regions may be coupled to energy transfer elements 810 and 816 by any suitable mechanism, such as, e.g., heat shrinking or the like.
The one or more active regions 826 of energy transfer elements 810 and/or 816 may include one or more temperature sensing elements 832. In one example, each active region 826 may include two temperature sensing elements 832 (e.g., thermocouples or the like), and each temperature sensing element 832 may include a lead 834 that is coupled to a controller and/or power source (not shown) of energy delivery array 800. Leads 834 may be routed proximally through proximal insulated regions 828, or in any other suitable configuration.
An activation element 836 may extend from proximal end 801 toward distal end 802 of energy delivery array 800. Activation element 836 may be substantially similar to activation element 104 described with reference to
Energy delivery array 800 may be configured to operate in a bipolar configuration, although other suitable configurations are also contemplated. First and second polar assemblies 803 and 804 may be insulated from one another by insulation elements 822 and 824. Insulation element 822 may be disposed between proximal end piece 806 of first polar assembly 803 and proximal end piece 812 of second polar assembly 804. Insulation element 824 may be disposed between distal end piece 808 of first polar assembly 803 and distal end piece 814 of second polar assembly 804. In some examples, insulation elements 822 and 824 may be generally disk shaped with a central aperture (e.g., insulating elements 822 and 824 may be insulating washers) although other suitable insulating configurations are also contemplated.
In some examples, activation element 836 may be configured to deliver energy from a controller and/or power source to distal end piece 814 and energy transfer elements 816 of second polar assembly 804. It is further contemplated that other activation elements (not shown) may also deliver energy to first polar assembly 802. In some examples, first polar assembly 803 and second polar assembly 804 may be separate poles of an RF circuit each with a different polarity supplied by the power source. In some examples, the polarities of the poles may oscillate at high frequency. As second polar assembly 804 may be insulated from first polar assembly 803, when energy delivery array is disposed within bodily lumens and tissues, RF energy may flow from second polar assembly 804, through bodily tissues, to proximal end piece 806, distal end piece 808, and energy transfer elements 816 of first polar assembly 803, heating the bodily tissues surrounding energy delivery array 800. Alternatively, energy may flow from first polar assembly 803, through bodily tissues, to second polar assembly 804.
The various catheters, electrode arrays, energy delivery arrays, and other devices disclosed in the specification may be coupled to one or more shafts and/or sheaths having a length in a range from about 0.5 feet to about 8.0 feet, or another suitable length. In some examples, the energy delivery arrays and/or baskets may have an expanded basket diameter in a range from about 1 mm to about 25 mm, or in another suitable range. In some examples, the exposed portions of an electrode leg, e.g., active regions 826, may be about 5 mm in length. In other examples, active regions 826 may be in the range from about 1 mm to 50 mm in length, or may have another suitable length.
In various examples of the present disclosure, RF energy may be applied to tissues defining a body lumen (e.g., a lung airway) for a length of time in the range of about 0.1 seconds to about 600 seconds. In one example, a power source may be capable of delivering about 1 to 100 watts of RF energy, and may possess continuous flow capability. The tissues defining a lung airway may be maintained at a temperature that is lesser than, equal to, or greater than ambient body temperature. In one example, the tissues may be maintained at at least about 60° C., between 70° C. to 95° C., and/or between 70° C. to 85° C. The RF power-level may generally range from about 0-30 W, or another suitable range. In some examples, the power source may operate at up to a 75° C. setting. In some examples, RF energy may be delivered in discrete activations of, e.g., 5 to 10 seconds per activation. The frequency of the RF energy may be from 300 to 1750 kHz. It should be noted that, in at least some examples, other suitable values for energy delivery times, wattage, airway temperature, RF electrode temperature, and RF frequency are also contemplated.
Moreover, while specific examples may have been illustrated and described collectively herein, it should be appreciated that any subsequent arrangement designed to achieve the same or similar purpose may be substituted for the specific examples described and shown herein. This disclosure is intended to cover any and all subsequent adaptations or variations of the various examples. For example, it is contemplated that the above-described exemplary method steps can occur consecutively, simultaneously, or in various order with each other and with other steps that could be included. Combinations of the above examples, and other examples not specifically described herein, will be apparent to those of ordinary skill in the art upon reviewing the present disclosure.
Other examples of the present disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the examples disclosed herein. It is intended that the specification and examples be considered as exemplary only, and departure in form and detail may be made without departing from the scope and spirit of the present disclosure as defined by the following claims.
This application claims the benefit of U.S. Provisional Application No. 61/864,292, filed Aug. 9, 2013, the disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
612724 | Hamilton | Oct 1898 | A |
1155169 | Starkweather | Sep 1915 | A |
1207479 | Bisgaard | Dec 1916 | A |
1216183 | Swingle | Feb 1917 | A |
2072346 | Smith | Mar 1937 | A |
3320957 | Sokolik | May 1967 | A |
3568659 | Karnegis | Mar 1971 | A |
3667476 | Muller | Jun 1972 | A |
3692029 | Adair | Sep 1972 | A |
3995617 | Watkins et al. | Dec 1976 | A |
4095602 | Leveen | Jun 1978 | A |
4116589 | Rishton | Sep 1978 | A |
4129129 | Amrine | Dec 1978 | A |
4154246 | Leveen | May 1979 | A |
4461283 | Doi | Jul 1984 | A |
4502490 | Evans et al. | Mar 1985 | A |
4503855 | Maslanka | Mar 1985 | A |
4512762 | Spears | Apr 1985 | A |
4522212 | Gelinas et al. | Jun 1985 | A |
4557272 | Carr | Dec 1985 | A |
4565200 | Cosman | Jan 1986 | A |
4567882 | Heller | Feb 1986 | A |
4584998 | McGrail | Apr 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4621642 | Chen | Nov 1986 | A |
4621882 | Krumme | Nov 1986 | A |
4625712 | Wampler | Dec 1986 | A |
4643186 | Rosen et al. | Feb 1987 | A |
4646737 | Hussein et al. | Mar 1987 | A |
4674497 | Ogasawara | Jun 1987 | A |
4683890 | Hewson | Aug 1987 | A |
4704121 | Moise | Nov 1987 | A |
4706688 | Don Michael et al. | Nov 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
4754065 | Levenson et al. | Jun 1988 | A |
4754752 | Ginsburg et al. | Jul 1988 | A |
4765959 | Fukasawa | Aug 1988 | A |
4772112 | Zider et al. | Sep 1988 | A |
4773899 | Spears | Sep 1988 | A |
4779614 | Moise | Oct 1988 | A |
4784135 | Blum et al. | Nov 1988 | A |
4790305 | Zoltan et al. | Dec 1988 | A |
4799479 | Spears | Jan 1989 | A |
4802492 | Grunstein | Feb 1989 | A |
4817586 | Wampler | Apr 1989 | A |
4825871 | Cansell | May 1989 | A |
4827935 | Geddes et al. | May 1989 | A |
4846152 | Wampler et al. | Jul 1989 | A |
4862886 | Clarke et al. | Sep 1989 | A |
4895557 | Moise et al. | Jan 1990 | A |
4906229 | Wampler | Mar 1990 | A |
4907589 | Cosman | Mar 1990 | A |
4908012 | Moise et al. | Mar 1990 | A |
4944722 | Carriker et al. | Jul 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4967765 | Turner et al. | Nov 1990 | A |
4969865 | Hwang et al. | Nov 1990 | A |
4976709 | Sand | Dec 1990 | A |
4985014 | Orejola | Jan 1991 | A |
4991603 | Cohen et al. | Feb 1991 | A |
5009636 | Wortley et al. | Apr 1991 | A |
5009936 | Yamanaka et al. | Apr 1991 | A |
5010892 | Colvin et al. | Apr 1991 | A |
5019075 | Spears et al. | May 1991 | A |
5027829 | Larsen | Jul 1991 | A |
5030645 | Kollonitsch | Jul 1991 | A |
5036848 | Hewson | Aug 1991 | A |
5053033 | Clarke | Oct 1991 | A |
5056519 | Vince | Oct 1991 | A |
5074860 | Gregory et al. | Dec 1991 | A |
5078716 | Doll | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5096916 | Skupin | Mar 1992 | A |
5100388 | Behl et al. | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5103804 | Abele et al. | Apr 1992 | A |
5105826 | Smits et al. | Apr 1992 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5107830 | Younes | Apr 1992 | A |
5114423 | Kasprzyk et al. | May 1992 | A |
5116864 | March et al. | May 1992 | A |
5117828 | Metzger et al. | Jun 1992 | A |
5135517 | McCoy | Aug 1992 | A |
5152286 | Sitko et al. | Oct 1992 | A |
5165420 | Strickland | Nov 1992 | A |
5167223 | Koros et al. | Dec 1992 | A |
5170803 | Hewson et al. | Dec 1992 | A |
5174288 | Bardy et al. | Dec 1992 | A |
5188602 | Nichols | Feb 1993 | A |
5191883 | Lennox et al. | Mar 1993 | A |
5213576 | Abiuso et al. | May 1993 | A |
5215103 | Desai | Jun 1993 | A |
5231996 | Bardy et al. | Aug 1993 | A |
5232444 | Just et al. | Aug 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5255678 | Deslauriers et al. | Oct 1993 | A |
5255679 | Imran | Oct 1993 | A |
5265604 | Vince | Nov 1993 | A |
5269758 | Taheri | Dec 1993 | A |
5281218 | Imran | Jan 1994 | A |
5292331 | Boneau | Mar 1994 | A |
5293869 | Edwards et al. | Mar 1994 | A |
5309910 | Edwards et al. | May 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5324284 | Imran | Jun 1994 | A |
5343936 | Beatenbough et al. | Sep 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5366443 | Eggers et al. | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5370679 | Atlee, III | Dec 1994 | A |
5374287 | Rubin | Dec 1994 | A |
5383917 | Desai et al. | Jan 1995 | A |
5393207 | Maher et al. | Feb 1995 | A |
5394880 | Atlee, III | Mar 1995 | A |
5396887 | Imran | Mar 1995 | A |
5400778 | Jonson et al. | Mar 1995 | A |
5400783 | Pomeranz et al. | Mar 1995 | A |
5411025 | Webster | May 1995 | A |
5415166 | Imran | May 1995 | A |
5415656 | Tihon et al. | May 1995 | A |
5417687 | Nardella et al. | May 1995 | A |
5422362 | Vincent et al. | Jun 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5425023 | Haraguchi et al. | Jun 1995 | A |
5425703 | Feiring | Jun 1995 | A |
5425811 | Mashita | Jun 1995 | A |
5431696 | Atlee, III | Jul 1995 | A |
5433730 | Alt | Jul 1995 | A |
5437665 | Munro | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5454782 | Perkins | Oct 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5474530 | Passafaro et al. | Dec 1995 | A |
5478309 | Sweezer et al. | Dec 1995 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5496312 | Klicek | Mar 1996 | A |
5500011 | Desai | Mar 1996 | A |
5505728 | Ellman et al. | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507791 | Sit'ko | Apr 1996 | A |
5509419 | Edwards et al. | Apr 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5545193 | Fleischman et al. | Aug 1996 | A |
5547469 | Rowland et al. | Aug 1996 | A |
5549559 | Eshel | Aug 1996 | A |
5549655 | Erickson | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
RE35330 | Malone et al. | Sep 1996 | E |
5558073 | Pomeranz et al. | Sep 1996 | A |
5562608 | Sekins et al. | Oct 1996 | A |
5571074 | Buckman et al. | Nov 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5574059 | Regunathan et al. | Nov 1996 | A |
5578072 | Barone et al. | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5588812 | Taylor et al. | Dec 1996 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5598848 | Swanson et al. | Feb 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5601088 | Swanson et al. | Feb 1997 | A |
5605157 | Panescu et al. | Feb 1997 | A |
5607419 | Amplatz et al. | Mar 1997 | A |
5607462 | Imran | Mar 1997 | A |
5620438 | Amplatz et al. | Apr 1997 | A |
5623940 | Daikuzono | Apr 1997 | A |
5624439 | Edwards et al. | Apr 1997 | A |
5626618 | Ward et al. | May 1997 | A |
5630425 | Panescu et al. | May 1997 | A |
5630794 | Lax et al. | May 1997 | A |
5634471 | Fairfax et al. | Jun 1997 | A |
5641326 | Adams | Jun 1997 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5678535 | Dimarco | Oct 1997 | A |
5680860 | Imran | Oct 1997 | A |
5681280 | Rusk et al. | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5693078 | Desai et al. | Dec 1997 | A |
5694934 | Edelman | Dec 1997 | A |
5695471 | Wampler | Dec 1997 | A |
5699799 | Xu et al. | Dec 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5707218 | Maher et al. | Jan 1998 | A |
5707336 | Rubin | Jan 1998 | A |
5707352 | Sekins et al. | Jan 1998 | A |
5722401 | Pietroski et al. | Mar 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5722416 | Swanson et al. | Mar 1998 | A |
5725525 | Kordis | Mar 1998 | A |
5727569 | Benetti et al. | Mar 1998 | A |
5728094 | Edwards | Mar 1998 | A |
5730128 | Pomeranz et al. | Mar 1998 | A |
5730704 | Avitall | Mar 1998 | A |
5730726 | Klingenstein | Mar 1998 | A |
5730741 | Horzewski et al. | Mar 1998 | A |
5735846 | Panescu et al. | Apr 1998 | A |
5740808 | Panescu et al. | Apr 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5755714 | Murphy-Chutorian | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5759158 | Swanson | Jun 1998 | A |
5765568 | Sweezer et al. | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5772590 | Webster | Jun 1998 | A |
5779669 | Haissaguerre et al. | Jul 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5782239 | Webster | Jul 1998 | A |
5782797 | Schweich et al. | Jul 1998 | A |
5782827 | Gough et al. | Jul 1998 | A |
5782848 | Lennox | Jul 1998 | A |
5782899 | Imran | Jul 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5795303 | Swanson et al. | Aug 1998 | A |
5800375 | Sweezer et al. | Sep 1998 | A |
5807306 | Shapland et al. | Sep 1998 | A |
5810757 | Sweezer et al. | Sep 1998 | A |
5810807 | Ganz et al. | Sep 1998 | A |
5817028 | Anderson | Oct 1998 | A |
5817073 | Krespi | Oct 1998 | A |
5820554 | Davis et al. | Oct 1998 | A |
5823189 | Kordis | Oct 1998 | A |
5827277 | Edwards | Oct 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5836905 | Lemelson et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5837001 | Mackey | Nov 1998 | A |
5843075 | Taylor | Dec 1998 | A |
5843077 | Edwards | Dec 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5848972 | Triedman et al. | Dec 1998 | A |
5849026 | Zhou et al. | Dec 1998 | A |
5855577 | Murphy-Chutorian et al. | Jan 1999 | A |
5860974 | Abele | Jan 1999 | A |
5863291 | Schaer | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5868740 | Leveen et al. | Feb 1999 | A |
5871443 | Edwards et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5873852 | Vigil et al. | Feb 1999 | A |
5873865 | Horzewski et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5881727 | Edwards | Mar 1999 | A |
5882346 | Pomeranz et al. | Mar 1999 | A |
5891135 | Jackson et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5891138 | Tu et al. | Apr 1999 | A |
5893847 | Kordis | Apr 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5899882 | Waksman et al. | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5904711 | Flom et al. | May 1999 | A |
5906636 | Casscells, III et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5908446 | Imran | Jun 1999 | A |
5908839 | Levitt et al. | Jun 1999 | A |
5911218 | Dimarco | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5919147 | Jain | Jul 1999 | A |
5919172 | Golba | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5931835 | Mackey | Aug 1999 | A |
5935079 | Swanson et al. | Aug 1999 | A |
5941869 | Patterson et al. | Aug 1999 | A |
5951494 | Wang et al. | Sep 1999 | A |
5951546 | Lorentzen | Sep 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5954662 | Swanson et al. | Sep 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
5957961 | Maguire et al. | Sep 1999 | A |
5964753 | Edwards | Oct 1999 | A |
5964796 | Imran | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5972026 | Laufer et al. | Oct 1999 | A |
5975303 | Morell | Nov 1999 | A |
5976175 | Hirano et al. | Nov 1999 | A |
5976709 | Kageyama et al. | Nov 1999 | A |
5979456 | Magovern | Nov 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
5984971 | Faccioli et al. | Nov 1999 | A |
5991650 | Swanson et al. | Nov 1999 | A |
5992419 | Sterzer et al. | Nov 1999 | A |
5993462 | Pomeranz et al. | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
5999855 | Dimarco | Dec 1999 | A |
6001054 | Regulla et al. | Dec 1999 | A |
6003517 | Sheffield et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6006755 | Edwards | Dec 1999 | A |
6008211 | Robinson et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6010500 | Sherman et al. | Jan 2000 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6016437 | Tu et al. | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6029091 | De La Rama et al. | Feb 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6036689 | Tu et al. | Mar 2000 | A |
6039731 | Taylor et al. | Mar 2000 | A |
6045549 | Smethers et al. | Apr 2000 | A |
6045550 | Simpson et al. | Apr 2000 | A |
6050992 | Nichols | Apr 2000 | A |
6053172 | Hovda et al. | Apr 2000 | A |
6053909 | Shadduck | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6056769 | Epstein et al. | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6071280 | Edwards et al. | Jun 2000 | A |
6071282 | Fleischman | Jun 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6090104 | Webster | Jul 2000 | A |
6092528 | Edwards | Jul 2000 | A |
6102886 | Lundquist et al. | Aug 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6139527 | Laufer et al. | Oct 2000 | A |
6139571 | Fuller et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6143013 | Samson et al. | Nov 2000 | A |
6149647 | Tu et al. | Nov 2000 | A |
6152143 | Edwards | Nov 2000 | A |
6152899 | Farley | Nov 2000 | A |
6159194 | Eggers et al. | Dec 2000 | A |
6165169 | Panescu et al. | Dec 2000 | A |
6179833 | Taylor | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6198970 | Freed et al. | Mar 2001 | B1 |
6200311 | Danek et al. | Mar 2001 | B1 |
6200332 | Del Giglio | Mar 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6210367 | Carr | Apr 2001 | B1 |
6212433 | Behl | Apr 2001 | B1 |
6214002 | Fleischman et al. | Apr 2001 | B1 |
6216043 | Swanson et al. | Apr 2001 | B1 |
6216044 | Kordis | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6241727 | Tu et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6264653 | Falwell | Jul 2001 | B1 |
6269813 | Fitzgerald et al. | Aug 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6273907 | Laufer | Aug 2001 | B1 |
6283988 | Laufer et al. | Sep 2001 | B1 |
6283989 | Laufer et al. | Sep 2001 | B1 |
6287304 | Eggers et al. | Sep 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6299633 | Laufer | Oct 2001 | B1 |
6319251 | Tu | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6322584 | Ingle et al. | Nov 2001 | B2 |
6338727 | Noda et al. | Jan 2002 | B1 |
6338836 | Kuth et al. | Jan 2002 | B1 |
6346104 | Daly et al. | Feb 2002 | B2 |
6355031 | Edwards et al. | Mar 2002 | B1 |
6379352 | Reynolds et al. | Apr 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6416740 | Unger | Jul 2002 | B1 |
6423105 | Iijima et al. | Jul 2002 | B1 |
6425895 | Swanson et al. | Jul 2002 | B1 |
6440129 | Simpson | Aug 2002 | B1 |
6442435 | King et al. | Aug 2002 | B2 |
6454775 | Demarais | Sep 2002 | B1 |
6458121 | Rosenstock et al. | Oct 2002 | B1 |
6460545 | Kordis | Oct 2002 | B2 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6494880 | Swanson et al. | Dec 2002 | B1 |
6496738 | Carr | Dec 2002 | B2 |
6514246 | Swanson et al. | Feb 2003 | B1 |
6526320 | Mitchell | Feb 2003 | B2 |
6529756 | Phan et al. | Mar 2003 | B1 |
6544226 | Gaiser et al. | Apr 2003 | B1 |
6544262 | Fleischman | Apr 2003 | B2 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6558378 | Sherman et al. | May 2003 | B2 |
6572612 | Stewart et al. | Jun 2003 | B2 |
6575623 | Werneth | Jun 2003 | B2 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6582427 | Goble et al. | Jun 2003 | B1 |
6582430 | Hall | Jun 2003 | B2 |
6589235 | Wong et al. | Jul 2003 | B2 |
6610054 | Edwards et al. | Aug 2003 | B1 |
6620159 | Hegde | Sep 2003 | B2 |
6626903 | McGuckin et al. | Sep 2003 | B2 |
6635056 | Kadhiresan et al. | Oct 2003 | B2 |
6638273 | Farley et al. | Oct 2003 | B1 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6645200 | Koblish et al. | Nov 2003 | B1 |
6652548 | Evans et al. | Nov 2003 | B2 |
6669693 | Friedman | Dec 2003 | B2 |
6673068 | Berube | Jan 2004 | B1 |
6692492 | Simpson et al. | Feb 2004 | B2 |
6699243 | West et al. | Mar 2004 | B2 |
6714822 | King et al. | Mar 2004 | B2 |
6723091 | Goble et al. | Apr 2004 | B2 |
6743197 | Edwards | Jun 2004 | B1 |
6749604 | Eggers et al. | Jun 2004 | B1 |
6749606 | Keast et al. | Jun 2004 | B2 |
6767347 | Sharkey et al. | Jul 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6802843 | Truckai et al. | Oct 2004 | B2 |
6805131 | Kordis | Oct 2004 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6840243 | Deem et al. | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6852091 | Edwards et al. | Feb 2005 | B2 |
6852110 | Roy et al. | Feb 2005 | B2 |
6866662 | Fuimaono et al. | Mar 2005 | B2 |
6881213 | Ryan et al. | Apr 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6893439 | Fleischman | May 2005 | B2 |
6895267 | Panescu et al. | May 2005 | B2 |
6904303 | Phan et al. | Jun 2005 | B2 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6954977 | Maguire et al. | Oct 2005 | B2 |
7027869 | Danek et al. | Apr 2006 | B2 |
7043307 | Zelickson et al. | May 2006 | B1 |
7104987 | Biggs et al. | Sep 2006 | B2 |
7104990 | Jenkins et al. | Sep 2006 | B2 |
7118568 | Hassett et al. | Oct 2006 | B2 |
7122033 | Wood | Oct 2006 | B2 |
7131445 | Amoah | Nov 2006 | B2 |
7186251 | Malecki et al. | Mar 2007 | B2 |
7198635 | Danek | Apr 2007 | B2 |
7200445 | Dalbec et al. | Apr 2007 | B1 |
7241295 | Maguire | Jul 2007 | B2 |
7255693 | Johnston et al. | Aug 2007 | B1 |
7266414 | Cornelius et al. | Sep 2007 | B2 |
7273055 | Danek et al. | Sep 2007 | B2 |
7357770 | Cutrer | Apr 2008 | B1 |
7425212 | Danek et al. | Sep 2008 | B1 |
7542802 | Biggs et al. | Jun 2009 | B2 |
7556624 | Laufer et al. | Jul 2009 | B2 |
7740017 | Danek et al. | Jun 2010 | B2 |
8161978 | Danek et al. | Apr 2012 | B2 |
8584681 | Dakek et al. | Nov 2013 | B2 |
20030050631 | Mody et al. | Mar 2003 | A1 |
20030065371 | Satake | Apr 2003 | A1 |
20030069570 | Witzel et al. | Apr 2003 | A1 |
20030187430 | Vorisek | Oct 2003 | A1 |
20030236455 | Swanson et al. | Dec 2003 | A1 |
20040153056 | Muller et al. | Aug 2004 | A1 |
20040249401 | Rabiner et al. | Dec 2004 | A1 |
20050010270 | Laufer | Jan 2005 | A1 |
20050096644 | Hall et al. | May 2005 | A1 |
20050096647 | Steinke | May 2005 | A1 |
20050171396 | Pankratov et al. | Aug 2005 | A1 |
20050193279 | Daners | Sep 2005 | A1 |
20050240176 | Oral et al. | Oct 2005 | A1 |
20050251128 | Amoah | Nov 2005 | A1 |
20060062808 | Michael et al. | Mar 2006 | A1 |
20060079887 | Buysse et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060135953 | Kania et al. | Jun 2006 | A1 |
20060137698 | Danek et al. | Jun 2006 | A1 |
20060247617 | Danek et al. | Nov 2006 | A1 |
20060247618 | Kaplan et al. | Nov 2006 | A1 |
20060247619 | Kaplan et al. | Nov 2006 | A1 |
20060247726 | Biggs et al. | Nov 2006 | A1 |
20060247727 | Biggs et al. | Nov 2006 | A1 |
20060247746 | Danek et al. | Nov 2006 | A1 |
20060282071 | Utley et al. | Dec 2006 | A1 |
20070074719 | Danek et al. | Apr 2007 | A1 |
20070083194 | Kunis et al. | Apr 2007 | A1 |
20070083197 | Danek et al. | Apr 2007 | A1 |
20070100390 | Danaek et al. | May 2007 | A1 |
20070106108 | Hermann et al. | May 2007 | A1 |
20070106292 | Kaplan et al. | May 2007 | A1 |
20070106296 | Laufer et al. | May 2007 | A1 |
20070106348 | Laufer | May 2007 | A1 |
20070118184 | Danek et al. | May 2007 | A1 |
20070118190 | Danek et al. | May 2007 | A1 |
20070123958 | Laufer | May 2007 | A1 |
20070123961 | Danek et al. | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20080004596 | Yun et al. | Jan 2008 | A1 |
20080125772 | Stone | May 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20080269539 | Cutrer et al. | Oct 2008 | A1 |
20090030477 | Jarrard | Jan 2009 | A1 |
20090043301 | Jerry et al. | Feb 2009 | A1 |
20090069797 | Danek et al. | Mar 2009 | A1 |
20090112203 | Danek et al. | Apr 2009 | A1 |
20090143705 | Danek et al. | Jun 2009 | A1 |
20090143776 | Danek et al. | Jun 2009 | A1 |
20090192505 | Askew et al. | Jul 2009 | A1 |
20090192508 | Laufer et al. | Jul 2009 | A1 |
20090306644 | Mayse et al. | Dec 2009 | A1 |
20110106074 | Kunis | May 2011 | A1 |
20110118726 | De La Rama | May 2011 | A1 |
20130218158 | Danek et al. | Aug 2013 | A1 |
Number | Date | Country |
---|---|---|
101309651 | Nov 2008 | CN |
19529634 | Feb 1997 | DE |
0189329 | Jul 1986 | EP |
189329 | Jun 1987 | EP |
0282225 | Sep 1988 | EP |
286145 | Oct 1988 | EP |
280225 | Mar 1989 | EP |
286145 | Oct 1990 | EP |
282225 | Jun 1992 | EP |
0768091 | Apr 1997 | EP |
0908150 | Apr 1999 | EP |
908713 | Apr 1999 | EP |
908150 | May 2003 | EP |
768091 | Jul 2003 | EP |
1297795 | Aug 2005 | EP |
2659240 | Sep 1991 | FR |
2233293 | Jan 1991 | GB |
2233293 | Feb 1994 | GB |
59167707 | Sep 1984 | JP |
7289557 | Nov 1995 | JP |
9047518 | Feb 1997 | JP |
9243837 | Sep 1997 | JP |
10026709 | Jan 1998 | JP |
2011-507656 | Mar 2011 | JP |
2012-508635 | Apr 2012 | JP |
2053814 | Feb 1996 | RU |
2091054 | Sep 1997 | RU |
545358 | Feb 1977 | SU |
WO-1989011311 | Nov 1989 | WO |
WO-1995002370 | Jan 1995 | WO |
WO-1995010322 | Apr 1995 | WO |
WO-1996004860 | Feb 1996 | WO |
WO-1996010961 | Apr 1996 | WO |
WO-1997032532 | Sep 1997 | WO |
WO-1997033715 | Sep 1997 | WO |
WO-1997037715 | Oct 1997 | WO |
WO-9740751 | Nov 1997 | WO |
WO-1998044854 | Oct 1998 | WO |
WO-1998052480 | Nov 1998 | WO |
WO-9856234 | Dec 1998 | WO |
WO-9858681 | Dec 1998 | WO |
WO-1998056324 | Dec 1998 | WO |
WO-1999003413 | Jan 1999 | WO |
WO-1998058681 | Mar 1999 | WO |
WO-1999013779 | Mar 1999 | WO |
WO-9913779 | May 1999 | WO |
WO-9932040 | Jul 1999 | WO |
WO-1999034741 | Jul 1999 | WO |
WO-1999044506 | Sep 1999 | WO |
WO-1999045855 | Sep 1999 | WO |
WO-9964109 | Dec 1999 | WO |
WO-2000051510 | Sep 2000 | WO |
WO-0062699 | Oct 2000 | WO |
WO-0062699 | Oct 2000 | WO |
WO-2001003642 | Jan 2001 | WO |
WO-0232333 | Apr 2002 | WO |
WO-0232334 | Apr 2002 | WO |
WO-2008049084 | Apr 2008 | WO |
WO-2009082433 | Jul 2009 | WO |
WO-2009137819 | Nov 2009 | WO |
Entry |
---|
An S.S., et al., “Airway Smooth Muscle Dynamics: A Common Pathway of Airway Obstruction in Asthma,” European Respiratory Journal, 2007, 29 (5), 834-860. |
Bel E.H., ““Hot stuff”: Bronchial Thermoplasty for Asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173 (9), 941-943. |
Brown R.H., et al., “Effect of Bronchial Thermoplasty on Airway Distensibility,” European Respiratory Journal, 2005, 26 (2), 277-282. |
Brown R.H., et al., “In Vivo evaluation of the Effectiveness of Bronchial Thermoplasty with Computed Tomography,” Journal of Applied Physiology, 2005, 98 (5), 1603-1606. |
Chhajed P.N., et al., “Will there be a Role for Bronchoscopic Radiofrequency Ablation”, Journal of Bronchology, 2005, 12 (3), 184-186. |
Abandoned U.S. Appl. No. 09/095,323, filed Jun. 10, 1998. |
Abandoned U.S. Appl. No. 09/244,173, filed Feb. 4, 1999. |
Co-pending U.S. Appl. No. 12/640,644, filed Dec. 17, 2009. |
Patented U.S. Appl. No. 12/727,156, filed Mar. 18, 2010. |
Patented U.S. Appl. No. 12/765,704, filed Apr. 22, 2010. |
Cox G., et al., “Asthma Control during the Year after Bronchial Thermoplasty,” New England journal of medicine, 2007, 356 (13), 1327-1337. |
Cox G., et al., “Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty: Early Results,” American Thoracic Society Annual Meeting, 2002, 1 page. |
Cox G., et al., “Bronchial Thermoplasty for Asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173 (9), 965-969. |
Cox G., et al., “Bronchial Thermoplasty: Long-Term Follow-Up and Patient Satisfaction,” Chest, 2004, 126 (4), 822s. |
Cox G., et al., “Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, A313. |
Cox G., et al., “Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma,” Chest, 2003, 124, 106S. |
Cox G., et al., “Development of a Novel Bronchoscopic Therapy for Asthma,” Journal of Allergy and Clinical Immunology, 2003, 113 (2), S33. |
Cox G., et al., “Early Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma,” American Thoracic Society Annual Meeting, 2002, 1068. |
Cox G., et al., “Impact of Bronchial Thermoplasty on Asthma Status: Interim Results from the AIR Trial,” 2006, 1 page. |
Cox G., et al., “Radiofrequency Ablation of Airway Smooth Muscle for Sustained Treatment of Asthma: Preliminary Investigations,” European Respiratory Journal, 2004, 24 (4), 659-663. |
Danek C.J., et al., “Bronchial Thermoplasty Reduces Canine Airway Responsiveness to Local Methacholine Challenge,” American Thoracic Society Annual Meeting, 2002, 1 page. |
Danek C.J., et al., “Reduction in Airway Hyperresponsiveness to Methacholine by the Application of RF Energy in Dogs,” Journal of Applied Physiology, 2004, 97 (5), 1946-1953. |
Dierkesmann R., “Indication and Results of Endobronchial Laser Therapy,” Lung, 1990, 168, 1095-1102. |
Global Strategy for Asthma Management and Prevention, National Institute of Health, National Heart, Lung and Blood Institute, 2002, 192 pages. |
Hogg J. C., “The Pathology of Asthma,” APMIS, 1997, 105 (10), 735-745. |
International Search Report for Application No. PCT/US00/05412, dated Jun. 20, 2000, 2 pages. |
International Search Report for Application No. PCT/US00/18197, dated Oct. 3, 2000, 1 page. |
International Search Report for Application No. PCT/US00/28745, dated Mar. 28, 2001, 6 pages. |
International Search Report for Application No. PCT/US01/32321, dated Jan. 18, 2002, 2 pages. |
International Search Report for Application No. PCT/US98/03759, dated Jul. 30, 1998, 1 page. |
International Search Report for Application No. PCT/US98/26227, dated Mar. 25, 1999, 1 page. |
International Search Report for Application No. PCT/US99/00232, dated Mar. 4, 1999, 1 page. |
International Search Report for Application No. PCT/US99/12986, dated Sep. 29, 1999, 1 page. |
Ivanyuta O.M., et al., “Effect of Low-Power Laser Irradiation of Bronchial Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza, 1991, 6, 26-29. |
James A.L., et al., “The Mechanics of Airway Narrowing in Asthma,” American Review of Respiratory Diseases, 1989, 139 (1), 242-246. |
Janssen L.J., “Asthma Therapy: How Far have We Come, Why did We Fail and Where should We Go Next ,” European Respiratory Journal, 2009, 33 (1), 11-20. |
Jeffery P.K, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal of Respiratory and Critical Care Medicine, 2001, 164 (10), S28-S38. |
Johnson S. R., et al., “Synthetic Functions of Airway Smooth Muscle in Asthma,” Trends Pharmacol. Sci., 1997, 18 (8), 288-292. |
Kitamura S., “Color Atlas of Clinical Application of Fiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 2 pages. |
Kraft M., “The Distal Airways: Are they Important in Asthma”, European Respiratory Journal, 1999, 14 (6), 1403-1417. |
Laviolette M., et al., “Asthma Intervention Research (Air) Trial: Early Safety Assessment of Bronchial Thermoplasty,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, A314. |
Leff A., et al., “Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs: A Possible Procedure for the Treatment of Asthma,” American Thoracic Society Annual Meeting, 2002, 1 page. |
Lim E.C., et al., “Botulinum Toxin: A Novel Therapeutic Option for Bronchial Asthma”, Medical Hypotheses, 2006, 66 (5), 915-919. |
Lombard C.M., et al., “Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways,” American Thoracic Society Annual Meeting, 2002, 1 page. |
Macklem P. T., “Mechanical Factors Determining Maximum Bronchoconstriction,” European Respiratory Journal, 1989, 6, 516s-519s. |
Mayse M.L., et al., “Clinical Pearls for Bronchial Thermoplasty,” Journal of Bronchology, 2007, 14 (2), 115-123. |
Miller J.D., et al., “A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway,” Chest, 2005, 127 (6), 1999-2006. |
Miller J.D., et al., “Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy,” American Thoracic Society Annual Meeting, 2002, 1 page. |
Mitzner W., “Airway Smooth Muscle the Appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169 (7), 787-790. |
Mitzner W., “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55 (3), 225-234. |
Netter F.H., “Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases,In The CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit: New Jerse,” 1979, 7, 119-135. |
Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages. |
Provotorov V.M., et al., “The Clinical Efficacy of Treating Patients with Nonspecific Lung Diseases Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration,” Terapevticheskii Arkhiv, 1991, 62 (12), 18-23. |
Rubin A., et al., “Bronchial Thermoplasty Improves Asthma Status of Moderate to Severe Perisstent Asthmatics Over and Above Current Standard-of-Care,” American College of Chest Physicians, 2006, 2 pages. |
Seow C.Y., et al., “Historical Perspective on Airway Smooth Muscle: The Saga of a Frustrated Cell,” Journal of Applied Physiology, 2001, 91 (2), 938-952. |
Shesterina M.V., et al., “Effect of Laser Therapy on Immunity in Patients with Bronchial Asthma and Pulmonary Tuberculosis,” Problemy Tuberkuleza, 1994, 5, 23-26. |
Shore S.A., “Airway Smooth Muscle in Asthma—Not Just More of the Same,” New England Journal of Medicine, 2004, 351 (6), 531-532. |
Solway J., et al., “Airway Smooth Muscle as a Target for Asthma Therapy,” New England Journal of medicine, 2007, 356 (13), 1367-1369. |
Sterk P.J., et al., “Heterogeneity of Airway Hyperresponsiveness: Time for Unconventional, But Traditional, Studies,” Journal of Applied Physiology, 2004, 96 (6), 2017-2018. |
Toma T.P., et al., “Brave New World for Interventional Bronchoscopy,” Thorax, 2005, 60 (3), 180-181. |
Trow T.K., “Clinical Year in Review I: Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology,” Proceedings of the American Thoracic Society, 2006, 3 (7), 553-556. |
UNSW Embryo-Respiratory System [online], Embryology, 2007, [retrieved on Dec. 10, 2007]. Retrieved from the internet: (URL:http://embryology.med.unsw.edu.au/Refer/respire/sclect.htm). |
Vasilotta P.L., et al., “I-R Laser: A New Therapy in Rhino-Sino-Nasal Bronchial Syndrome with Asthmatic Component,” American Society for Laser Medicine and Surgery Abstracts, 74. 1993. |
Vorotnev A.I., et al., “The Treatment of Patients with Chronic Obstructive Bronchitis by Using a Low-power Laser at a General Rehabilitation Center,” Terapevticheskii Arkhiv, 1997, 69 (3), 17-19. |
Wiggs B.R., et al., “On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways,” Journal of Applied Physiology, 1997, 83 (6), 1814-1821. |
Wilson S.R., et al., “Global Assessment after Bronchial Thermoplasty: The Patients Perspective,” Journal of Outcomes Research, 2006, 10, 37-46. |
Wizeman W., et al., “A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery,” American Thoracic Society Annual Meeting, 2007, 1 page. |
Patented U.S. Appl. No. 09/436,455, filed Nov. 8, 1999. |
International Search Report for Application No. PCT/US2014/050204, dated Oct. 24, 2014, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20150045788 A1 | Feb 2015 | US |
Number | Date | Country | |
---|---|---|---|
61864292 | Aug 2013 | US |